MRNA vs PCVX
MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines. PCVX: Vaxcyte is a clinical-stage vaccine company leveraging a novel cell-free protein synthesis platform to develop next-generation, broad-spectrum pneumococcal conjugate vaccines.
Side-by-side fundamentals
| Metric | MRNA | PCVX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $197.00 | $65.02 | |
| Market cap | $78.6B | $9.7B | |
| Net margin FY2025, SEC XBRL | -145.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -158.1% | n/a | |
| ROE FY2025, SEC XBRL | -32.6% | -28.5% | PCVX higher |
| ROA FY2025, SEC XBRL | -22.9% | -25.5% | MRNA higher |
| Debt / equity as of 2026-09-03 | 0.09 | 0.00 | PCVX lower |
| Revenue growth (YoY) as of 2026-09-03 | -27.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -53.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.39 | 0.89 | |
| 1-year return as of 2026-10-08 close | +605.6% | +59.6% | MRNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.